Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gamma-aminobutyric acid type A receptor alpha 1 subunit (GABRA1) is a key component of the GABA_A receptor, the primary inhibitory neurotransmitter receptor in the central nervous system. It is a ligand-gated chloride channel that, upon activation by GABA, allows chloride ions to flow into the neuron, resulting in hyperpolarization and reduced neuronal excitability. GABRA1 is widely expressed in the brain and plays a critical role in regulating neuronal activity, sleep, anxiety, and seizure susceptibility. Mutations in the *GABRA1* gene and dysregulation of GABRA1-containing GABA_A receptors are implicated in various neurological disorders, including epilepsy.
Binding of GABA to the GABRA1 subunit within the GABA_A receptor complex leads to the opening of a chloride channel, resulting in increased chloride conductance, hyperpolarization of the neuron, and inhibition of neuronal firing. Allosteric modulators such as benzodiazepines and barbiturates enhance GABA's effect by increasing the frequency or duration of channel opening.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor alpha 1 subunit (GABRA1).